Product Images Levetiracetam In Sodium Chloride

This text provides information about a medication called Levetiracetam, which is administered intravenously in 0.54% Sodium Chloride Injection. Each 100mL contains 1,500 mg of Levetiracetam to be infused over a period of 15 minutes. It warns against using plastic containers in series connections and not diluting the solution further. The storage recommendation is between 20°C to 25°C. The product has a single-dose dual port bag with an aluminum overwrap and the closure does not contain natural rubber latex. The manufacturer is HIKMA FARMACEUTICA (PORTUGAL), S.A, and it is distributed by Hikma Pharmaceuticals USA Inc.*

This is a medication label containing information about an injectable solution with NDC number 0143-9283-10. It is recommended to infuse the medication over a period of 15 minutes. The solution contains 1,500 mg of vetiaceam, water for injection, sodium chloride, glacial acetic acid, and other components. The dosage instructions are available in the package insert. Caution is advised to check for impurities before using the container. The medication should not be used with plastic containers with inseal connections. The label also includes instructions on how to open the container and storage recommendations. The product is for intravenous infusion only and is manufactured by a pharmaceutical company based in Portugal.*

This text appears to be a table comparing the effectiveness of different doses of Levetiracetam compared to a placebo in relation to a certain outcome. The table also mentions the percentage of patients in each group and highlights that the results are statistically significant versus placebo. Specific values are given for the different doses of Levetiracetam and the placebo group, and the sample sizes for each group are also provided.*

This text appears to be detailing the percentage breakdown of a study comparing the effectiveness of different dosages of Levetiracetam versus a Placebo in a group of participants. The study suggests that the 2000 mg/day dosage of Levetiracetam is statistically significant compared to the Placebo based on the provided percentages.*

This text appears to show percentage values related to patients in a study, with specific values indicated as statistically significant versus placebo. It also lists the dosage of Levetiracetam used in the study (3000 mg/day) and the number of patients in each group (104 for placebo and 180 for Levetiracetam). The data seems to be related to medical research or clinical trials.*

This text appears to be showing the results of a study comparing the effectiveness of a placebo and Levetiracetam in a certain condition. The percentile values represent the percentage of patients achieving a specific outcome. The statement "*statistically significant versus placebo" indicates that there were significant differences between the two groups in terms of the measured outcome.*

This text provides information about a medication called Levetiracetam in 0.82% Sodium Chloride Injection, with a concentration of 500 mg per 100 mL. It is intended for intravenous infusion over a 15-minute period. The solution also contains water for injection, sodium chloride, glacial acetic acid, and sodium acetate. The usual dosage instructions are included, and caution is advised against using series connections or diluting the solution further. The storage conditions, manufacturer, and distributor details are provided as well. The medication is packaged in a single-dose dual port bag with aluminum overwrap, and the container closure does not contain natural rubber latex.*

This text is a detailed description of a medication package containing Levetiracetam in 0.82% Sodium Chloride Injection. It provides information on the dosage, instructions for use, storage recommendations, and manufacturer details. The medication is meant for intravenous infusion only and should be administered over a period of 15 minutes. The package includes 10 single-dose bags, each with 500 mg of Levetiracetam per 100 mL. It also includes caution instructions regarding leakage and advises against further dilution before use. The text further mentions not using plastic containers in series connections and specifies that the container closure is not made with natural rubber latex.*

This text is a medication label for Levetiracetam in 0.75% Sodium Chloride Injection, containing 1,000 mg per 100 mL for intravenous infusion only. It provides instructions on dosage and administration, cautions about storage conditions, and mentions precautions like not using plastic containers for intravenous infusion. The medication is manufactured by Hikma Farmageutica in Portugal and distributed by Hikma Pharmaceuticals USA.*

This text appears to be a description of a pharmaceutical product with the National Drug Code (NDC) 0143-9282-10 for intravenous infusion. The product contains Levetiracetam, sodium chloride, acetic acid, and sodium acetate in specific concentrations. It is intended for use over a 15-minute period and should not be used in plastic containers. The usual dosage should be referred to the package insert. The product is presented in 100 mL single-dose bags. Manufacturer information includes Hikma Pharmaceuticals in Portugal. The text also mentions specific precautions and instructions for use.*